Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing …
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
NEW YORK and LONDON, January 6, 2021 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Participate in Two January Virtual Investor Conferences
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and …
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially …
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BPThe Phase II data was the basis for the agreement of the …
